ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO756

Impact of Bemiparin, a Low Molecular Weight Heparin, in the Oxidative Stress of Patients in Chronic Hemodialysis

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Medina, Elba O., Hospital General de Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico
  • Valdez-Ortiz, Rafael, Hospital General de Mexico, Mexico City, DIStrito federal, Mexico
  • Perez-Navarro, L. Monserrat, Hospital General de México Dr. Eduardo Liceaga, México, Mexico
  • Tapia Lopez, Josue Wigberto, ISSSTE, Estado de Mexico, DIStrito federal, Mexico
Background

Patients in hemodialysis (HD) has increased oxidative stress (OS), what it produces endothelial damage secondary to the generation of reactive oxygen species (ROS), and consequently progression of cardiovascular disease (CVD). It has been observed, that the use of low molecular weight heparin (LMWH) could decrease the OS in this patients. We evaluated the effect of bemiparine a LMWH on the OS of patients in chronic HD.

Methods

Randomized, open, single-blind controlled clinical trial in chronic HD patients: group with UFH (n=19) as standard anticoagulation during HD and group with LMWH (n= 19). The OS markers were measured basal, at 4 and at 8 weeks: malondialdehyde (MDA), total antioxidant capacity (TAC), Superoxide Dismutase (SOD), Nitric Oxide synthase (NOS), Catalase (CAT) and Peroxidase (POD). Student's t-test, one-way ANOVA were performed.

Results

The mean age of the study groups was 33.5± 4.4 years. The comparison between groups did not present statistically significant differences in markers of OS. While, the intragroup comparison group with LMWH, was statistically significant differences in the levels of TAC (basal vs intermediate and, basal vs final); CAT (Intermediate vs final) and POD (intermediate vs final); while, the group with UFH showed statistically significant differences (p≤ 0.05) in the levels of POD (basal vs final), see Figure 1. None of the groups presented events of thrombosis or hemorrhagic complications.

Conclusion

There was a prospective increase in the concentration of OS markers in the LMWH group, what it demonstrates that the continuous use of LMWH participates in the antioxidant defense against the generation of ROS and the OS of patients with CKD in HD. It is necessary to evaluate the long-term use of LMWH on oxidative stress markers and evaluate the possible benefit of it use in the reduction of cardiovascular mortality.